← All trials
NCT07088757
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2025
- Primary completion
- Nov 1, 2026
- Completion date
- Dec 1, 2026
- First posted
- Jul 28, 2025
- Last posted
- Nov 18, 2025
- Enrollment
- 1366
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Changhai HospitalLead sponsor
- People's Hospital of QuzhouCollaborator
- Dongyang People's HospitalCollaborator
- Changhai HospitalSponsor investigator
- Nanchang UniversityCollaborator
- Jinhua Central HospitalCollaborator
- Shaoxing People's HospitalCollaborator
- Zhejiang UniversityCollaborator
- Ningbo UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Taizhou Enze Medical Center GroupCollaborator
- Zhuji People's Hospital of Zhejiang ProvinceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.